Eli Lilly and Company (LLY) : The total money flow in Eli Lilly and Company (LLY) was negative ($2.91 million), showing the domination of sellers in the Wednesday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $24.9 million. Transactions on upticks were comparatively lower at $21.99 million. The uptick to downtick ratio was 0.88. The total block trades done on upticks were valued at $5 million. The total block trades on downticks were valued at $0.88 million. The uptick to the downtick ratio of block trades was 5.67. The money flow during block trades was negative ($4.12 million) when the stock traded with a gain of $27 cent. Eli Lilly and Company (LLY) was $80.24, an increase of 0.33% over the previous days close.
Also, Jefferies maintains its rating on Eli Lilly and Company (NYSE:LLY). The global brokerage major raises the current price target from $100 per share to $105 per share. Analysts at the Jefferies have a current rating of Buy on the shares. The rating by the firm was issued on July 14, 2016.
Eli Lilly and Company (NYSE:LLY): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $80.27 and $79.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.52. The buying momentum continued till the end and the stock did not give up its gains. It closed at $80.28, notching a gain of 0.39% for the day. The total traded volume was 2,811,087 . The stock had closed at $79.97 on the previous day.
The stock has recorded a 20-day Moving Average of 3.1% and the 50-Day Moving Average is 5.4%. In a related news, The officer (Chief Eth/Cmpl Ofcr & SVP, ERM), of Lilly Eli & Co, Barnes Melissa S had unloaded 992 shares at $73.77 per share in a transaction on June 10, 2016. The total value of transaction was $73,180. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.